Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab). …
Positive efficacy result for Immutep’s 'efti' in combination with MSD's KEYTRUDA
October 23, 2023 Australian Biotech
Latest Video
New Stories
-
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News -
Australian company secures Mitsubishi partnership to bring BioPQQ to market
August 26, 2026 - - Latest News -
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech -
Argent BioPharma takes CannEpil into US veterinary regulatory process
August 26, 2026 - - Latest News -
Entropy takes TRP-8803 to the US in head-to-head depression trial
August 26, 2026 - -
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech